---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-01-11T14:54:56.247423'
end_time: '2026-01-11T15:01:39.175587'
duration_seconds: 402.93
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: ASCL1
  gene_symbol: ASCL1
  uniprot_accession: P50553
  protein_description: 'RecName: Full=Achaete-scute homolog 1 {ECO:0000303|PubMed:8390674};
    Short=ASH-1 {ECO:0000303|PubMed:8390674}; Short=hASH1 {ECO:0000303|PubMed:8390674};
    AltName: Full=Class A basic helix-loop-helix protein 46 {ECO:0000312|HGNC:HGNC:738};
    Short=bHLHa46 {ECO:0000312|HGNC:HGNC:738};'
  gene_info: Name=ASCL1 {ECO:0000312|HGNC:HGNC:738}; Synonyms=ASH1, BHLHA46 {ECO:0000312|HGNC:HGNC:738},
    HASH1 {ECO:0000303|PubMed:8390674};
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: bHLH_dom. (IPR011598); HLH_DNA-bd_sf. (IPR036638); MASH1/Ascl1a-like.
    (IPR015660); HLH (PF00010)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 32
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P50553
- **Protein Description:** RecName: Full=Achaete-scute homolog 1 {ECO:0000303|PubMed:8390674}; Short=ASH-1 {ECO:0000303|PubMed:8390674}; Short=hASH1 {ECO:0000303|PubMed:8390674}; AltName: Full=Class A basic helix-loop-helix protein 46 {ECO:0000312|HGNC:HGNC:738}; Short=bHLHa46 {ECO:0000312|HGNC:HGNC:738};
- **Gene Information:** Name=ASCL1 {ECO:0000312|HGNC:HGNC:738}; Synonyms=ASH1, BHLHA46 {ECO:0000312|HGNC:HGNC:738}, HASH1 {ECO:0000303|PubMed:8390674};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** bHLH_dom. (IPR011598); HLH_DNA-bd_sf. (IPR036638); MASH1/Ascl1a-like. (IPR015660); HLH (PF00010)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "ASCL1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'ASCL1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **ASCL1** (gene ID: ASCL1, UniProt: P50553) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P50553
- **Protein Description:** RecName: Full=Achaete-scute homolog 1 {ECO:0000303|PubMed:8390674}; Short=ASH-1 {ECO:0000303|PubMed:8390674}; Short=hASH1 {ECO:0000303|PubMed:8390674}; AltName: Full=Class A basic helix-loop-helix protein 46 {ECO:0000312|HGNC:HGNC:738}; Short=bHLHa46 {ECO:0000312|HGNC:HGNC:738};
- **Gene Information:** Name=ASCL1 {ECO:0000312|HGNC:HGNC:738}; Synonyms=ASH1, BHLHA46 {ECO:0000312|HGNC:HGNC:738}, HASH1 {ECO:0000303|PubMed:8390674};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** bHLH_dom. (IPR011598); HLH_DNA-bd_sf. (IPR036638); MASH1/Ascl1a-like. (IPR015660); HLH (PF00010)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "ASCL1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'ASCL1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **ASCL1** (gene ID: ASCL1, UniProt: P50553) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan overview and identity verification
- Identity check: The target is human ASCL1 (achaete-scute family bHLH transcription factor 1), UniProt P50553, a nuclear basic helix–loop–helix (bHLH) transcription factor also known as MASH1/hASH1. Literature and recent studies consistently describe ASCL1 as a proneural bHLH factor with nuclear localization and canonical bHLH DNA-binding/HLH dimerization domains, matching the UniProt domain annotations (bHLH_dom; HLH_DNA-bd superfamily). These features and nomenclature align with the human protein specified by the user (https://doi.org/10.1158/1541-7786.mcr-23-0405, Mar 2024; https://doi.org/10.1097/cm9.0000000000002693, Sep 2024) (liu2024distinctregulationof pages 1-2, guo2024molecularclassificationof pages 1-2).

Key concepts and definitions with current understanding
- Molecular identity and cellular localization: ASCL1 is a class A bHLH transcription factor that binds E-box motifs (CANNTG) as a heterodimer with E-proteins (e.g., TCF3/E12/E47). It functions in the nucleus to drive neuronal and neuroendocrine gene programs (https://doi.org/10.1158/1541-7786.mcr-23-0405) (liu2024distinctregulationof pages 1-2).
- Molecular function and pioneer-like activity: ASCL1 exhibits pioneer-factor properties, binding nucleosome-occupied DNA and promoting chromatin opening at neuronal enhancers to initiate lineage programs. Its binding is enriched at E-box–dense enhancers, and E-protein association facilitates nucleosomal engagement (https://doi.org/10.1098/rsob.250018, Jun 2025) (lundiebrown2025cellfateacquisition pages 9-11, lundiebrown2025cellfateacquisition pages 11-12).
- Direct transcriptional targets and pathway positioning: ASCL1 directly activates neuroendocrine/neural effectors including INSM1, MYT1, and multiple neuroendocrine markers, and it transcriptionally upregulates Notch-modulatory ligands such as DLL1/DLL3. This places ASCL1 upstream of Notch repression in neuroendocrine lineages, where DLL3 acts as an inhibitory Notch ligand (https://doi.org/10.1172/jci175217, Jul 2024; https://doi.org/10.1158/2767-9764.crc-24-0501, Feb 2025) (ku2024notchsignalingsuppresses pages 1-2, lozada2025expressionpatternsof pages 1-2). Additional ASCL1 targets frequently cited in SCLC include CHGA, CALCB, and RET (OpenTargets summary of curated evidence) (OpenTargets Search: Small cell lung cancer,Neuroblastoma-ASCL1).
- Biological roles: In development, ASCL1 is a proneural factor required for neuronal differentiation and neuroendocrine lineage specification. In cancer, it is a lineage-defining oncoprotein that maintains neuroendocrine identity and survival programs, particularly in the ASCL1-dominant subtype of small cell lung cancer (SCLC-A) (https://doi.org/10.1097/cm9.0000000000002693) (guo2024molecularclassificationof pages 1-2).

Recent developments and latest research (prioritize 2023–2024)
- Post-translational and cell-cycle regulation (2024): In SCLC, ASCL1 protein abundance is dynamically regulated by the cell cycle. CDK2–CyclinA2 phosphorylates ASCL1, promoting proteasome-mediated degradation during mitosis via the E3 ligase HUWE1; interaction with the E-protein TCF3 protects ASCL1 from degradation, and chemotherapy decreases ASCL1 transcription while ASCL1 depletion sensitizes cells to chemotherapy (https://doi.org/10.1158/1541-7786.mcr-23-0405, Mar 2024) (liu2024distinctregulationof pages 1-2). Broader mechanistic syntheses similarly emphasize HUWE1-mediated ubiquitination and E-protein–dependent stabilization as central regulatory nodes (Molecules review, 2025) (huang2025molecularsubtypesand pages 6-7).
- Oncogenic lineage role and subtype prevalence (2024): Molecular classification work consolidates ASCL1 as the dominant lineage-defining TF in SCLC-A, with reported prevalence around 70–75% of tumors. This classification corresponds to distinct biology, microenvironment features, and therapeutic vulnerabilities (https://doi.org/10.1097/cm9.0000000000002693, Sep 2024) (guo2024molecularclassificationof pages 1-2). OpenTargets curation likewise highlights subtype-specific dependency on ASCL1 in SCLC models (OpenTargets Search: Small cell lung cancer,Neuroblastoma-ASCL1).
- ASCL1–Notch axis across neuroendocrine cancers (2024): In advanced prostate cancer, activation of Notch suppresses neuroendocrine differentiation; DLL3 is an inhibitory Notch ligand transcriptionally activated by ASCL1, reinforcing the conserved ASCL1–DLL3–Notch axis in neuroendocrine states (https://doi.org/10.1172/jci175217, Jul 2024) (ku2024notchsignalingsuppresses pages 1-2).
- Drug tolerance and plasticity (2024): In EGFR-mutant lung adenocarcinoma PDXs, osimertinib treatment can induce ASCL1 upregulation in residual disease, where ASCL1 drives an EMT-like program conferring drug tolerance in permissive cellular contexts. This connects ASCL1 to therapy-induced lineage plasticity beyond classical SCLC (https://doi.org/10.1158/0008-5472.can-23-0438, Feb 2024) (hu2024ascl1drivestolerance pages 1-3).
- Tumor evolution under therapy (2024): Longitudinal multi-region sequencing in SCLC reveals branched evolution and relapse from ancestral clones under therapy. While genomic states dominated the analysis, these data contextualize how lineage programs (including ASCL1-driven states) are embedded within evolving clonal architectures (https://doi.org/10.1038/s41586-024-07177-7, Mar 2024) (ku2024notchsignalingsuppresses pages 1-2).
- Multi-omics trajectories (2024): Recent multi-omics analyses of neuroendocrine trans-differentiation identify ASCL1 as a master regulator with bifurcating lineage endpoints and reciprocal relationships with other lineage TFs (e.g., ASCL2/POU2F3), consistent with ASCL1’s role in shaping neuroendocrine states (2024 study) (chen2024multiomicstranscriptionalprofiling pages 74-78).

Current applications and real-world implementations
- Subtype classification and biomarker use: ASCL1 immunohistochemistry/RNA profiling is used to classify SCLC into lineage subtypes; ASCL1-high (SCLC-A) tumors display neuroendocrine programs and distinct vulnerabilities. Estimates place SCLC-A at ~70–75% of SCLC, with NEUROD1, POU2F3, and immune-inflamed subtypes comprising the remainder (https://doi.org/10.1097/cm9.0000000000002693) (guo2024molecularclassificationof pages 1-2).
- DLL3-targeted therapies linked to ASCL1 programs: DLL3, commonly activated by ASCL1 and serving as a Notch inhibitor, is widely expressed in neuroendocrine malignancies. Tarlatamab, a DLL3×CD3 bispecific T-cell engager (BiTE), achieved objective responses around 40% in previously treated SCLC in phase II and received FDA approval in 2024 for chemotherapy-refractory extensive-stage SCLC, illustrating rapid clinical translation of ASCL1→DLL3 biology (Cancer Research Communications, 2025; Frontiers in Immunology, 2025; see also JCI 2024 for ASCL1→DLL3 regulation) (https://doi.org/10.1158/2767-9764.crc-24-0501; https://doi.org/10.3389/fimmu.2025.1592291; https://doi.org/10.1172/jci175217) (lozada2025expressionpatternsof pages 2-3, lozada2025expressionpatternsof pages 1-2, ji2025harnessingdeltalikeligand pages 1-2, ku2024notchsignalingsuppresses pages 1-2, ji2025harnessingdeltalikeligand pages 5-6).
- Broader modalities: DLL3-targeted strategies under investigation include next-generation bispecifics (e.g., HPN328), CAR T/NK constructs, radioimmunoconjugates, and photoimmunotherapy, with early clinical signals of activity and evolving safety profiles (https://doi.org/10.3389/fimmu.2025.1592291) (ji2025harnessingdeltalikeligand pages 5-6). Historical DLL3 ADCs (rovalpituzumab tesirine) showed response enrichment in DLL3-high tumors but were discontinued due to toxicity and inferior survival in later studies, informing current modality choices (https://doi.org/10.1158/2767-9764.crc-24-0501) (lozada2025expressionpatternsof pages 6-7).

Expert opinions and analysis from authoritative sources
- Nature/clinical oncology synthesis: A 2024 Nature Reviews Clinical Oncology perspective emphasizes the centrality of lineage-defining TFs (ASCL1, NEUROD1, POU2F3) in SCLC biology, the existence of plasticity between subtypes, and the therapeutic implications for patient stratification and resistance management (https://doi.org/10.1038/s41571-024-00914-x, Jul 2024) (huang2025molecularsubtypesand pages 6-7). The Nature 2024 tumor-evolution study further underscores the complexity of relapse and the need to integrate lineage programs with clonal dynamics to optimize therapy (https://doi.org/10.1038/s41586-024-07177-7, Mar 2024) (ku2024notchsignalingsuppresses pages 1-2).
- Mechanistic regulation consensus: Experimental work (MCR 2024) and synthesis (Open Biology 2025) converge on a model where ASCL1’s function is tuned by multi-site phosphorylation (CDK/ERK pathways), ubiquitin-mediated turnover (HUWE1), chromatin engagement that is stabilized by E-proteins (TCF3), and feedback with Notch signaling via DLL ligands (https://doi.org/10.1158/1541-7786.mcr-23-0405; https://doi.org/10.1098/rsob.250018) (liu2024distinctregulationof pages 1-2, lundiebrown2025cellfateacquisition pages 11-12).

Relevant statistics and recent quantitative data
- Prevalence of ASCL1-high SCLC: Approximately 70–75% of SCLC classified as SCLC-A/ASCL1-dominant, based on recent clinical-molecular reviews (Sep 2024) (https://doi.org/10.1097/cm9.0000000000002693) (guo2024molecularclassificationof pages 1-2). OpenTargets curation corroborates high frequency of ASCL1 dependency in SCLC models (OpenTargets Search: Small cell lung cancer,Neuroblastoma-ASCL1).
- DLL3 prevalence: DLL3 overexpression in neuroendocrine tumors is common (~70–80% in SCLC); high DLL3 correlates with aggressive histology and adverse outcomes in multiple NEN sites, supporting biomarker-driven selection (Cancer Research Communications 2025; Frontiers in Immunology 2025) (https://doi.org/10.1158/2767-9764.crc-24-0501; https://doi.org/10.3389/fimmu.2025.1592291) (lozada2025expressionpatternsof pages 1-2, lozada2025expressionpatternsof pages 2-3, ji2025harnessingdeltalikeligand pages 1-2).
- SCLC survival context: SCLC remains highly lethal with very low 5-year overall survival (often <7%), underscoring the need for subtype- and biomarker-driven therapeutics such as DLL3-directed agents (Frontiers in Immunology 2025) (https://doi.org/10.3389/fimmu.2025.1592291) (ji2025harnessingdeltalikeligand pages 5-6).
- Clinical activity of DLL3 BiTE: Tarlatamab has shown approximately 40% objective response rates in previously treated SCLC in phase II, forming the basis for regulatory approval and ongoing integration into practice (CRC 2025) (https://doi.org/10.1158/2767-9764.crc-24-0501) (lozada2025expressionpatternsof pages 2-3).

Mechanistic details: pathways, targets, and regulation
- Pathways and targets: ASCL1 directly activates neuroendocrine transcriptional modules (e.g., INSM1, MYT1) and induces DLL1/DLL3, which modulate Notch signaling to support neuroendocrine differentiation; ASCL1 also co-regulates programs with other TFs in pulmonary neuroendocrine cells and SCLC-A (e.g., NKX2-1, PROX1 reported in curated compendia) (JCI 2024; OpenTargets) (https://doi.org/10.1172/jci175217) (ku2024notchsignalingsuppresses pages 1-2, OpenTargets Search: Small cell lung cancer,Neuroblastoma-ASCL1).
- Post-translational control: CDK2–CyclinA2-mediated phosphorylation and HUWE1-dependent ubiquitination regulate ASCL1 turnover during mitosis; E-protein (TCF3) association protects ASCL1 from degradation and coordinates DNA binding. Chemotherapy downregulates ASCL1 transcription, and genetic depletion enhances chemosensitivity in SCLC models (MCR 2024) (https://doi.org/10.1158/1541-7786.mcr-23-0405) (liu2024distinctregulationof pages 1-2). Phosphorylation status modulates chromatin opening and reprogramming potency, linking ASCL1 function to kinase signaling (Open Biology 2025) (https://doi.org/10.1098/rsob.250018) (lundiebrown2025cellfateacquisition pages 11-12).
- Chromatin engagement: ASCL1 binds nucleosomal DNA and remodels chromatin to pioneer neuronal/neuroendocrine enhancers, with E-proteins enhancing nucleosome affinity and occupancy at E-box-rich regions (Open Biology 2025) (https://doi.org/10.1098/rsob.250018) (lundiebrown2025cellfateacquisition pages 9-11, lundiebrown2025cellfateacquisition pages 11-12).

Clinical and translational implications
- Diagnostic and stratification use: ASCL1 expression supports SCLC molecular subtyping (SCLC-A), which correlates with neuroendocrine marker expression (INSM1, SYP, CHGA) and potential therapeutic vulnerabilities. Subtype-aware management is increasingly incorporated in trials and translational pipelines (https://doi.org/10.1097/cm9.0000000000002693) (guo2024molecularclassificationof pages 1-2).
- DLL3 as a therapeutic conduit of ASCL1 programs: ASCL1-driven DLL3 expression provides a tumor-restricted target across neuroendocrine malignancies. Tarlatamab’s 2024 approval in refractory SCLC and observed ~40% response rate in trials exemplify biomarker-guided immunotherapy based on ASCL1 biology. Alternative platforms (HPN328 TriTAC, CAR T/NK, RIT) are being refined to optimize efficacy/safety and address resistance mechanisms such as DLL3 loss (https://doi.org/10.1158/2767-9764.crc-24-0501; https://doi.org/10.3389/fimmu.2025.1592291) (lozada2025expressionpatternsof pages 2-3, lozada2025expressionpatternsof pages 6-7, ji2025harnessingdeltalikeligand pages 5-6).
- Therapy resistance/plasticity: ASCL1-driven gene programs can contribute to drug tolerance and lineage plasticity under targeted therapy pressure (osimertinib in EGFR-mutant tumors), suggesting that intercepting ASCL1 function or its downstream programs may mitigate residual disease (https://doi.org/10.1158/0008-5472.can-23-0438) (hu2024ascl1drivestolerance pages 1-3).

Structured summary
| Aspect | Key points (1–2 sentences) | Recent sources (Year; journal; DOI/URL) |
|---|---|---|
| Identity / domain & localization | Human ASCL1 (UniProt P50553) is a nuclear basic helix–loop–helix (bHLH) proneural transcription factor with canonical bHLH/MASH1 family features and nuclear localization. | Liu 2024; Molecular Cancer Research; https://doi.org/10.1158/1541-7786.mcr-23-0405 (Mar 2024) (liu2024distinctregulationof pages 1-2), Guo 2024; Chinese Medical Journal; https://doi.org/10.1097/cm9.0000000000002693 (Sep 2024) (guo2024molecularclassificationof pages 1-2), Open Targets summary (OpenTargets Search: Small cell lung cancer,Neuroblastoma-ASCL1) |
| Molecular function & pioneer activity | ASCL1 functions as a proneural bHLH transcription factor and exhibits pioneer-like chromatin engagement: binds E-box motifs, accesses nucleosomal DNA, and can open chromatin to activate neuronal programs. | Lundie-Brown 2025; Open Biology; https://doi.org/10.1098/rsob.250018 (lundiebrown2025cellfateacquisition pages 9-11, lundiebrown2025cellfateacquisition pages 11-12) |
| Direct targets & pathways (INSM1, MYT1, DLL1/DLL3; Notch axis) | ASCL1 activates neuroendocrine/neural programs including INSM1 and MYT1 and drives expression of Notch-modulatory ligands (DLL1, DLL3), placing ASCL1 upstream of Notch repression in NE lineages. | Ku 2024; J Clin Invest; https://doi.org/10.1172/jci175217 (Jul 2024) (ku2024notchsignalingsuppresses pages 1-2), Chen 2024; multi-omics SCLC study (chen2024multiomicstranscriptionalprofiling pages 74-78), Open Targets summary (OpenTargets Search: Small cell lung cancer,Neuroblastoma-ASCL1) |
| Regulation (cell cycle, phosphorylation, ubiquitination, E-proteins) | ASCL1 is cell-cycle regulated: CDK2–CyclinA2 phosphorylation and HUWE1-mediated ubiquitination control mitotic degradation; heterodimerization with E-proteins (e.g., TCF3) stabilizes DNA-bound ASCL1. | Liu 2024; Molecular Cancer Research; https://doi.org/10.1158/1541-7786.mcr-23-0405 (liu2024distinctregulationof pages 1-2), Lundie-Brown 2025; Open Biology (lundiebrown2025cellfateacquisition pages 11-12) |
| Role in SCLC (subtypes, prevalence, dependency) | ASCL1 defines the SCLC-A (neuroendocrine) lineage and is required for tumor initiation/survival in ASCL1-high tumors; reported prevalence for ASCL1-dominant SCLC is ~70–75%. | Guo 2024; Chinese Medical Journal; https://doi.org/10.1097/cm9.0000000000002693 (guo2024molecularclassificationof pages 1-2), Liu 2024; MCR (liu2024distinctregulationof pages 1-2), Open Targets summary (OpenTargets Search: Small cell lung cancer,Neuroblastoma-ASCL1) |
| Plasticity / therapy resistance (EGFR-mutant tolerance) | ASCL1 upregulation can drive drug-tolerant states and lineage plasticity (e.g., EMT-like programs) and has been implicated in tolerance to EGFR TKI osimertinib in permissive contexts. | Hu 2024; Cancer Research; https://doi.org/10.1158/0008-5472.can-23-0438 (Feb 2024) (hu2024ascl1drivestolerance pages 1-3), Chen 2024 multi-omics (chen2024multiomicstranscriptionalprofiling pages 74-78) |
| Clinical / translational applications (biomarker, DLL3 targeting, tarlatamab) | ASCL1 stratifies SCLC subtypes and correlates with DLL3 expression; DLL3-directed therapies (BiTEs/CARs) advanced clinically — tarlatamab (DLL3×CD3 BiTE) reported strong activity in refractory SCLC (~ORR ≈40% in phase II) and regulatory progress in 2024. | Lozada 2025; Cancer Res Commun; https://doi.org/10.1158/2767-9764.crc-24-0501 (Feb 2025) (lozada2025expressionpatternsof pages 2-3, lozada2025expressionpatternsof pages 1-2), Ji 2025; Frontiers Immunology; https://doi.org/10.3389/fimmu.2025.1592291 (May 2025) (ji2025harnessingdeltalikeligand pages 5-6), Open Targets summary (OpenTargets Search: Small cell lung cancer,Neuroblastoma-ASCL1) |
| Quantitative statistics | Reported metrics: DLL3 expression in NE tumors ~70–80%; SCLC-A accounts for ~70–75% of SCLC cases; SCLC 5‑year overall survival remains very low (<~7% reported in recent reviews). | DLL3 prevalence & DLL3–clinical data: Lozada 2025 (lozada2025expressionpatternsof pages 1-2, lozada2025expressionpatternsof pages 2-3), SCLC-A prevalence: Liu 2024 (liu2024distinctregulationof pages 1-2), Guo 2024 (guo2024molecularclassificationof pages 1-2); SCLC survival context: Ji 2025 / reviews (ji2025harnessingdeltalikeligand pages 5-6) |


*Table: Compact 2023–2024–focused evidence summary for human ASCL1 (UniProt P50553) summarizing identity, mechanisms, pathways, regulation, role in SCLC, plasticity, clinical applications and key quantitative stats with primary recent sources cited for each item.*

Conclusion
Human ASCL1 (UniProt P50553) is a nuclear bHLH transcription factor with pioneer-like chromatin activity that drives neuronal and neuroendocrine programs. It directly upregulates neuroendocrine effectors (e.g., INSM1, MYT1) and Notch-modulatory ligands (DLL1/DLL3), establishing a regulatory axis in which ASCL1 promotes neuroendocrine differentiation while repressing Notch signaling via DLL3. In cancer, ASCL1 defines the dominant SCLC-A lineage (~70–75%) and is essential for tumor maintenance in ASCL1-high models. Recent studies (2023–2024) clarify its cell-cycle/post-translational control (CDK2–CyclinA2 phosphorylation; HUWE1 ubiquitination; TCF3 stabilization), its role in therapy-induced plasticity, and its translational linkage to DLL3-targeted immunotherapies, including the 2024 FDA approval of tarlatamab for refractory SCLC. These advances underscore ASCL1’s centrality in neuroendocrine biology and its value as a biomarker and mechanistic anchor for emerging precision therapies (liu2024distinctregulationof pages 1-2, lundiebrown2025cellfateacquisition pages 9-11, huang2025molecularsubtypesand pages 6-7, chen2024multiomicstranscriptionalprofiling pages 74-78, hu2024ascl1drivestolerance pages 1-3, lundiebrown2025cellfateacquisition pages 11-12, guo2024molecularclassificationof pages 1-2, lozada2025expressionpatternsof pages 2-3, lozada2025expressionpatternsof pages 6-7, lozada2025expressionpatternsof pages 1-2, ji2025harnessingdeltalikeligand pages 1-2, ku2024notchsignalingsuppresses pages 1-2, ji2025harnessingdeltalikeligand pages 5-6).

References

1. (liu2024distinctregulationof pages 1-2): Yuning Liu, Qingzhe Wu, Bin Jiang, Tingting Hou, Chuanqiang Wu, Ming Wu, and Hai Song. Distinct regulation of ascl1 by the cell cycle and chemotherapy in small cell lung cancer. Molecular Cancer Research, 22:613-624, Mar 2024. URL: https://doi.org/10.1158/1541-7786.mcr-23-0405, doi:10.1158/1541-7786.mcr-23-0405. This article has 7 citations and is from a peer-reviewed journal.

2. (guo2024molecularclassificationof pages 1-2): Hanfei Guo, Wenqian Li, Ye Guo, Naifei Chen, and Jiuwei Cui. Molecular classification of small cell lung cancer subtypes: characteristics, prognostic factors, and clinical translation. Chinese Medical Journal, 137:130-139, Sep 2024. URL: https://doi.org/10.1097/cm9.0000000000002693, doi:10.1097/cm9.0000000000002693. This article has 5 citations and is from a peer-reviewed journal.

3. (lundiebrown2025cellfateacquisition pages 9-11): Jethro Lundie-Brown, Francesca Puletti, Anna Philpott, and Roberta Azzarelli. Cell fate acquisition and reprogramming by the proneural transcription factor ascl1. Open Biology, Jun 2025. URL: https://doi.org/10.1098/rsob.250018, doi:10.1098/rsob.250018. This article has 3 citations and is from a peer-reviewed journal.

4. (lundiebrown2025cellfateacquisition pages 11-12): Jethro Lundie-Brown, Francesca Puletti, Anna Philpott, and Roberta Azzarelli. Cell fate acquisition and reprogramming by the proneural transcription factor ascl1. Open Biology, Jun 2025. URL: https://doi.org/10.1098/rsob.250018, doi:10.1098/rsob.250018. This article has 3 citations and is from a peer-reviewed journal.

5. (ku2024notchsignalingsuppresses pages 1-2): Sheng-Yu Ku, Yanqing Wang, Maria Mica Garcia, Yasutaka Yamada, Kei Mizuno, Mark D. Long, Spencer Rosario, Meenalakshmi Chinnam, Majd Al Assaad, Loredana Puca, Min Jin Kim, Martin K. Bakht, Varadha Balaji Venkadakrishnan, Brian D. Robinson, Andrés M. Acosta, Kristine M. Wadosky, Juan Miguel Mosquera, David W. Goodrich, and Himisha Beltran. Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancer. The Journal of Clinical Investigation, Jul 2024. URL: https://doi.org/10.1172/jci175217, doi:10.1172/jci175217. This article has 29 citations.

6. (lozada2025expressionpatternsof pages 1-2): John R. Lozada, Andrew Elliott, Mark G. Evans, James Wacker, Kathleen M. Storey, Emily A. Egusa, Nicholas A. Zorko, Akhilesh Kumar, Anthony Crymes, Elisabeth I. Heath, Benedito A. Carneiro, Heloisa P. Soares, Frank Cichocki, Jeffrey S. Miller, Emil Lou, Himisha Beltran, Emmanuel S. Antonarakis, Charles J. Ryan, and Justin H. Hwang. Expression patterns of dll3 across neuroendocrine and non-neuroendocrine neoplasms reveal broad opportunities for therapeutic targeting. Cancer Research Communications, 5:318-326, Feb 2025. URL: https://doi.org/10.1158/2767-9764.crc-24-0501, doi:10.1158/2767-9764.crc-24-0501. This article has 8 citations and is from a peer-reviewed journal.

7. (OpenTargets Search: Small cell lung cancer,Neuroblastoma-ASCL1): Open Targets Query (Small cell lung cancer,Neuroblastoma-ASCL1, 4 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

8. (huang2025molecularsubtypesand pages 6-7): Daoyuan Huang, Jingchao Wang, Li Chen, Weiwei Jiang, Hiroyuki Inuzuka, David K. Simon, and Wenyi Wei. Molecular subtypes and targeted therapeutic strategies in small cell lung cancer: advances, challenges, and future perspectives. Molecules, 30:1731, Apr 2025. URL: https://doi.org/10.3390/molecules30081731, doi:10.3390/molecules30081731. This article has 12 citations and is from a poor quality or predatory journal.

9. (hu2024ascl1drivestolerance pages 1-3): Bomiao Hu, Marc Wiesehöfer, Fernando J. de Miguel, Zongzhi Liu, Lok-Hei Chan, Jungmin Choi, Mary Ann Melnick, Anna Arnal Estape, Zenta Walther, Dejian Zhao, Francesc Lopez-Giraldez, Anna Wurtz, Guoping Cai, Rong Fan, Scott Gettinger, Andrew Xiao, Qin Yan, Robert Homer, Don X. Nguyen, and Katerina Politi. Ascl1 drives tolerance to osimertinib in egfr mutant lung cancer in permissive cellular contexts. Cancer research, 84:1303-1319, Feb 2024. URL: https://doi.org/10.1158/0008-5472.can-23-0438, doi:10.1158/0008-5472.can-23-0438. This article has 25 citations and is from a highest quality peer-reviewed journal.

10. (chen2024multiomicstranscriptionalprofiling pages 74-78): CC Chen. Multi-omics transcriptional profiling of neuroendocrine trans-differentiation in small cell carcinoma. Unknown journal, 2024.

11. (lozada2025expressionpatternsof pages 2-3): John R. Lozada, Andrew Elliott, Mark G. Evans, James Wacker, Kathleen M. Storey, Emily A. Egusa, Nicholas A. Zorko, Akhilesh Kumar, Anthony Crymes, Elisabeth I. Heath, Benedito A. Carneiro, Heloisa P. Soares, Frank Cichocki, Jeffrey S. Miller, Emil Lou, Himisha Beltran, Emmanuel S. Antonarakis, Charles J. Ryan, and Justin H. Hwang. Expression patterns of dll3 across neuroendocrine and non-neuroendocrine neoplasms reveal broad opportunities for therapeutic targeting. Cancer Research Communications, 5:318-326, Feb 2025. URL: https://doi.org/10.1158/2767-9764.crc-24-0501, doi:10.1158/2767-9764.crc-24-0501. This article has 8 citations and is from a peer-reviewed journal.

12. (ji2025harnessingdeltalikeligand pages 1-2): Kangkang Ji, Lin Guo, Dianbao Zuo, Mingqian Feng, Xin Chen, Zhenggang Zhao, Jing Tang, and Guoping Chen. Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer. Frontiers in Immunology, May 2025. URL: https://doi.org/10.3389/fimmu.2025.1592291, doi:10.3389/fimmu.2025.1592291. This article has 2 citations and is from a peer-reviewed journal.

13. (ji2025harnessingdeltalikeligand pages 5-6): Kangkang Ji, Lin Guo, Dianbao Zuo, Mingqian Feng, Xin Chen, Zhenggang Zhao, Jing Tang, and Guoping Chen. Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer. Frontiers in Immunology, May 2025. URL: https://doi.org/10.3389/fimmu.2025.1592291, doi:10.3389/fimmu.2025.1592291. This article has 2 citations and is from a peer-reviewed journal.

14. (lozada2025expressionpatternsof pages 6-7): John R. Lozada, Andrew Elliott, Mark G. Evans, James Wacker, Kathleen M. Storey, Emily A. Egusa, Nicholas A. Zorko, Akhilesh Kumar, Anthony Crymes, Elisabeth I. Heath, Benedito A. Carneiro, Heloisa P. Soares, Frank Cichocki, Jeffrey S. Miller, Emil Lou, Himisha Beltran, Emmanuel S. Antonarakis, Charles J. Ryan, and Justin H. Hwang. Expression patterns of dll3 across neuroendocrine and non-neuroendocrine neoplasms reveal broad opportunities for therapeutic targeting. Cancer Research Communications, 5:318-326, Feb 2025. URL: https://doi.org/10.1158/2767-9764.crc-24-0501, doi:10.1158/2767-9764.crc-24-0501. This article has 8 citations and is from a peer-reviewed journal.

## Citations

1. liu2024distinctregulationof pages 1-2
2. guo2024molecularclassificationof pages 1-2
3. huang2025molecularsubtypesand pages 6-7
4. ku2024notchsignalingsuppresses pages 1-2
5. chen2024multiomicstranscriptionalprofiling pages 74-78
6. ji2025harnessingdeltalikeligand pages 5-6
7. lozada2025expressionpatternsof pages 6-7
8. lozada2025expressionpatternsof pages 2-3
9. lundiebrown2025cellfateacquisition pages 11-12
10. lundiebrown2025cellfateacquisition pages 9-11
11. lozada2025expressionpatternsof pages 1-2
12. ji2025harnessingdeltalikeligand pages 1-2
13. https://doi.org/10.1158/1541-7786.mcr-23-0405,
14. https://doi.org/10.1097/cm9.0000000000002693,
15. https://doi.org/10.1158/1541-7786.mcr-23-0405
16. https://doi.org/10.1098/rsob.250018,
17. https://doi.org/10.1172/jci175217,
18. https://doi.org/10.1158/2767-9764.crc-24-0501,
19. https://doi.org/10.1097/cm9.0000000000002693
20. https://doi.org/10.1158/0008-5472.can-23-0438,
21. https://doi.org/10.1038/s41586-024-07177-7,
22. https://doi.org/10.1158/2767-9764.crc-24-0501;
23. https://doi.org/10.3389/fimmu.2025.1592291;
24. https://doi.org/10.1172/jci175217
25. https://doi.org/10.3389/fimmu.2025.1592291
26. https://doi.org/10.1158/2767-9764.crc-24-0501
27. https://doi.org/10.1038/s41571-024-00914-x,
28. https://doi.org/10.1158/1541-7786.mcr-23-0405;
29. https://doi.org/10.1098/rsob.250018
30. https://doi.org/10.1158/0008-5472.can-23-0438
31. https://doi.org/10.3390/molecules30081731,
32. https://doi.org/10.3389/fimmu.2025.1592291,